art 1 of this Commentary argued that the risk sponsors should worry about is not concentration but variability, and that the benchmarking data shows Multisite Clinical Research Corporations, or MCRCs, compress that variability without sacrificing quality. If the diagnosis holds, the practical question follows: What should sponsors do to successfully manage this variability, and what must MCRCs offer in return? The answer starts where regulators have been pointing for a decade.

Regulatory Tailwind

Globally, regulators have pushed sponsors toward prospective, risk-based quality management. ICH E6(R3), the FDA’s work on quality by design, and the Clinical Trials Transformation Initiative quality framework all ask the same thing of sponsors: Build quality in at the design stage and manage risk across the trial rather than inspecting for it at the end. This is where MCRCs earn their keep.

When a sponsor works with 50 independent sites, it manages 50 separate quality systems and 50 separate risk profiles. When it allocates the same volume to an MCRC, it manages one of each. Centralized processes give the sponsor a single point of accountability, which is exactly what a risk-based quality framework is designed to reward. Rather than fight the direction of regulation, network-level allocation leans into it.

Power of Scale, Read Honestly

The concentration-risk objection has an empirical answer, and it is worth stating objectively rather than overclaiming. Velocity’s internal confidential data from 2024 onwards shows that adding more in-network sites to a study increases contracted enrollment and decreases screen-fail rates. As protocol complexity climbs year on year, sponsors appear to be realizing more value from organizations that can deliver scale, standardized processes, and operational consistency.

This honest version of the power-of-scale argument is more persuasive than a sweeping claim precisely because it survives scrutiny. Scale within one accountable entity improves realized enrollment. It is the same narrowing of variabilities described in part 1, seen from the recruitment side.

That evidence does not simply rest on one sponsor’s data. Across seven blinded Velocity case studies spanning six therapeutic areas—closed between 2024 and 2026—the same pattern holds regardless of sponsor or indication:

Exhibit: Velocity Case Study Portfolio, 2024–2026 (Blinded)

*Site-share and patient-share figures were not available in the source data for this case and are left blank rather than estimated.

F1 and F2 are two related studies within the same hemagglutinin vaccine program.

*Site-share and patient-share figures were not available in the source data for this case and are left blank rather than estimated.

F1 and F2 are two related studies within the same hemagglutinin vaccine program.

The range tells the story as much as any single number: Velocity’s share of total trial sites in these studies ran from roughly one-tenth to one-half, yet realized enrollment against contracted goal never fell below 100% and reached as high as 400%. This is the reduction of variability from part 1 made visible in delivery: Allocate meaningful volume to one accountable network—in modest or large measure—and the outcome is dependably at or above commitment, not a coin flip that depends on which fraction of sites a sponsor happened to pick.

Two honesty checks, in the same spirit as the single-sponsor data we chose not to use above:

1. This is a curated set of studies chosen to illustrate the pattern, not a random or exhaustive sample of Velocity’s full portfolio; readers should view it as illustrative rather than statistically comprehensive.
2. Three of these seven studies are vaccine trials, a study type that can enroll patients faster in more accessible populations; the pattern holds across the nonvaccine studies too, but the vaccine-heavy skew is worth naming rather than obscuring.

Trust Must Run Both Ways

If allocation is going to replace selection, it needs the scaffolding that made the CRO partnerships work. The strategic relationships that succeeded in the 2000s were the ones that built in metrics, governance, and shared accountability from the first day. Many of the relationships that failed were built on little more than goodwill and a handshake. The same is true here.

Sponsors should ask for reliability scoring, standardized key performance indicators, transparent visibility into process and infrastructure, and bilateral commitments that put obligations on both sides. But transparency cannot run in only one direction. Much of the industry conversation treats the site as the party that must open its books while the sponsor watches. Real partnership does not work that way. Sponsors need to trust sites as much as sites trust sponsors.

Bringing a network in early, sharing the shape of the incoming work, and discussing protocol design with sites before they are locked can dramatically alter the success of a subsequent trial. MCRCs can hire and train ahead of need, confirm they have the sites, therapeutic expertise, and patient access the program will require, and flag capacity constraints while there is still time to address them. A network that knows what is coming can prepare for it; a network that is kept in the dark can only react. Trusting a partner with sensitive information is a real shift in behavior, but this is the type of trust that makes network-level allocation deliver excellent results.

Watching Quality in Real Time

One underrated benefit of the entity model (MCRC) is visibility. Because an MCRC runs common systems across its sites, it can take the pulse of a trial’s quality while the trial is still running, rather than discovering problems at database lock. Deviations surface faster and get resolved faster when the same processes and the same dashboards span the whole network. For a sponsor, this means fewer surprises and a shorter distance between a problem appearing and its solution being found. This has shown up in screening success with a recent diabetes program where highly varied screen failure rates among sites revealed entirely different local practices to pre-screening that could be fine-tuned for better patient selection; eDiary completion rates in the 80 percents at one site compared to more than 90% at 10 other sites revealed an intervention opportunity to improve patient engagement, and, in turn, data compliance. Real-time quality oversight is difficult to achieve across a scatter of independent sites but is a natural property of a network.

Velocity’s own data illustrate the point. Its centralized Electronic Data Capture model is now entering 97% of clinical trial data within one business day of the patient visit—more than four times faster than the five-to-10-day industry average reported in independent benchmarking research from Veeva’s industry survey on clinical data management. That speed comes from replacing the traditional model—where entry speed and quality vary from coordinator to coordinator, site to site—with a single, purpose-built data-entry team trained to one standard and measured against one benchmark, network-wide. The payoff for sponsors is well-prepared monitoring visits, faster query resolution, and a shorter path to database lock: real-time visibility turned into a measured number instead of an abstract promise. Less variability.

Risks of Getting This Wrong

None of this is automatic, and it would be dishonest to pretend that this model has no failure modes. They are, tellingly, the same traps into which the CRO market fell:

• Overstandardization can strip out the local flexibility that complex trials sometimes need.
• Network-level allocation, applied bluntly, can shut out smaller sites that bring genuine access to specific patient populations.
• The language of quality by design can decay into a buzzword that decorates conference slides without changing how anyone works.

An MCRC earns the right to allocated volume by understanding where the model breaks and building to avoid it. This starts by naming these risks.

Practical First Step

Sponsors do not need to overhaul their outsourcing strategy to test any of this. But, in the next 12 months, they can allocate a defined slice of volume to a single MCRC under a bilateral agreement with shared KPIs and measure the results against their own site-by-site baseline: activation speed, deviation rates, realized enrollment, and, above all, the predictability of each. The comparison will be its own argument. What MCRCs must do is make that conversation straightforward enough: publish the metrics, commit to them, and stand behind network-level outcomes.

The drug development industry spent the 1990s learning that buying reliability rather than capacity was the smarter way to engage CROs. The site layer is now at the same threshold. Sponsors that move first, and MCRCs that give them the metrics and commitments to move with confidence, will spend the rest of this decade running more predictable trials than their competitors. This is not a marketing claim. It is what happens when you manage the risk that actually matters.

I’d welcome the chance to compare notes with any sponsor already thinking this through.